Innoviva (INVA) Equity Average (2011 - 2026)
Innoviva (INVA) reported Equity Average of $1.3 billion for Q1 2026, up 87.92% on a YoY basis from $669.0 million in Q1 2025, and up 15.2% quarter-over-quarter from $1.1 billion in Q4 2025.
Innoviva (INVA) Equity Average (2011 - 2026) Analysis & Trends
Innoviva has reported Equity Average for 16 years, with the latest figure at $1.3 billion in Q1 2026.
- For the quarter ending Q1 2026, Equity Average rose 87.92% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 87.92% YoY), and the FY2025 full-year result was $1.1 billion, up 60.53% from the prior year.
- Equity Average for Q1 2026 stood at $1.3 billion, up from $1.1 billion in the prior quarter.
- The five-year high for Equity Average was $1.3 billion in Q1 2026, with the low at $539.1 million in Q1 2022.
- Historically, Equity Average has averaged $703.0 million across 5 years, with a median of $667.0 million in 2024.
- Annual changes were most pronounced in 2022 — Equity Average declined 17.35% — and 2026, when it jumped 87.92%.
- Innoviva's Equity Average stood at $603.6 million in 2022, then grew by 7.89% to $651.2 million in 2023, then increased by 4.4% to $679.9 million in 2024, then surged by 60.53% to $1.1 billion in 2025, then climbed by 15.2% to $1.3 billion in 2026.
- The last three Equity Average figures came in at $1.3 billion (Q1 2026), $1.1 billion (Q4 2025), and $862.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 21.35 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 516.41 Mn |
| 10 | Innoviva | 1.69 Bn | 1.08 Bn | 75.83 Mn | 1.26 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.26 Bn |
| Dec 31, 2025 | 1.09 Bn |
| Sep 30, 2025 | 862.39 Mn |
| Jun 30, 2025 | 680.86 Mn |
| Mar 31, 2025 | 669.03 Mn |
| Dec 31, 2024 | 679.85 Mn |
| Sep 30, 2024 | 667.03 Mn |
| Jun 30, 2024 | 684.60 Mn |
| Mar 31, 2024 | 689.32 Mn |
| Dec 31, 2023 | 651.22 Mn |
| Sep 30, 2023 | 591.29 Mn |
| Jun 30, 2023 | 558.29 Mn |
| Mar 31, 2023 | 563.64 Mn |
| Dec 31, 2022 | 603.58 Mn |
| Sep 30, 2022 | 603.42 Mn |
| Jun 30, 2022 | 558.84 Mn |
| Mar 31, 2022 | 539.08 Mn |
| Dec 31, 2021 | 508.87 Mn |
| Sep 30, 2021 | 442.78 Mn |
| Jun 30, 2021 | 545.21 Mn |